Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tangshenkang capsule for stage III-IV diabetic nephropathy
ChiCTR-IPR-17013758Phase 4Recruiting
- Sponsor
- Gansu Provincial Hospital of Traditional Chinese Medicine
- Start
- Mar 2016
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Tangshen'an in diabetic glomerulosclerosis (2 arms), sponsored by Gansu Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Neutrophil-to-lymphocyte ratio, 24-hour total urine protein and 5 more. Started Mar 2016; status: recruiting.
02
Drugs
Tangshen'an
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR-IPR-17013758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013758.